• Vistin Pharma’s third-quarter 2026 net profit fell 41% year over year to NOK 11 million.
• Revenue slipped to NOK 108.4 million, with a stronger Norwegian krone against the euro offsetting increased sales volume.
• For the first nine months of 2026, revenue dropped 6% year over year to NOK 321 million.
• Shareholders will receive an additional cash dividend of NOK 0.50 per share in November.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vistin Pharma ASA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290245OMX_____CNEWS_EN_GNW1001280436_en) on October 29, 2026, and is solely responsible for the information contained therein.